Peptech: Domantis signs licence agreement with Tanox
09:50, Wednesday, 23 March 2005
Sydney - Wednesday - March 23: (RWE Australian Business News) -
Peptech Ltd (PTD) today announced the signing of a collaboration and
licence agreement between Domantis Ltd (UK) and Tanox Inc (USA) for the
use of domain antibodies in the treatment of autoimmune diseases.
As part of the deal Domantis, the domain antibody therapeutics
company in which Peptech holds a 36.1 per cent interest, will receive an
undisclosed upfront fee, research funding and annual fees, as well as
milestones and royalties on the therapeutic products developed and
commercialised by Tanox.
Tanox, a leading US biotechnology company, already has a
successful history in developing antibody therapeutics, which includes
the asthma drug Xolair.
Once buy-back starts, PTD will move to 2.00
PTD
unknown
